

FOI Request re Number of Patients Treated

Please detail the number of Oncology patients treated¹ (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months **January 2018 to December 2018** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated (regardless of Tumour Type)	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	0	0	0	0	0	0
Nivolumab (Opdivo)	0	0	0	0	0	0
Ipilimumab (Yervoy)	0	0	0	0	0	0
Nivolumab & Ipilimumab	0	0	0	0	0	0
Dabrafenib (Tafinlar)	10	9	0	0	0	0
Cabozantinib (Cabometyx)	0	0	0	0	0	0
Sunitinib (Sutent)	0	0	0	0	0	0
Pazopanib (Votrient)	1	0	0	0	0	0
Axitinib (Inlyta)	0	0	0	0	0	0
Atezolizumab (Tecentriq)	0	0	0	0	0	0
Sorafenib (Nexavar)	0	0	0	0	0	0
Tivozanib (Fotivda)	0	0	0	0	0	0
Cetuximab (Erbix)	0	0	0	0	0	0
Everolimus (Afinitor)	0	0	0	0	0	0
Vemurafenib (Zelboraf)	0	0	0	0	0	0
Total Number Treated (all treatments)	11	9	0	0	0	0

¹ Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).